Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

 
• By Andrew McConaghie

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments.   

Kidney
lupus nephritis overwhelmingly affects young, non-white women.

More from Business

More from Scrip